<DOC>
	<DOC>NCT01371162</DOC>
	<brief_summary>This 2-part, randomized, double-blind, placebo-controlled study will assess the safety, pharmacokinetics and pharmacodynamics of RO5428029 in healthy volunteers and patients with hepatitis C infection. Cohorts will be randomized to receive either RO5428029 in ascending doses or placebo for up to 7 days (patients) or up to 14 days (healthy volunteers).</brief_summary>
	<brief_title>A Study of RO5428029 in Healthy Volunteers and Patients With Chronic Hepatitis C</brief_title>
	<detailed_description />
	<mesh_term>Hepatitis</mesh_term>
	<mesh_term>Hepatitis C</mesh_term>
	<mesh_term>Hepatitis C, Chronic</mesh_term>
	<criteria>Healthy subjects (Part A) or patients with chronic hepatitis C infection (Part B), 18 to 60 years of age, inclusive Body mass index (BMI) between 18 and 32 kg/m2, inclusive, and a minimum weight of 45 kg Female subjects/patients must be surgically sterile or postmenopausal Male subjects/patients and their partners of childbearing potential must use 2 methods of contraception For HCV patients: Hepatitis C genotype 1 of &gt; 6 months duration at screening HCV RNA quantifiable (Roche COBAS TaqMan HCV Test) at screening HCV treatmentna√Øve (no prior antiviral therapy for chronic hepatitis C with interferonbased therapy) Liver biopsy or noninvasive procedure within the past 2 years showing absence of cirrhosis Pregnant or lactating women, and male partners of women who are pregnant or lactating Positive test for drugs of abuse History (within 3 months of screening) of alcohol consumption exceeding 2 standard drinks per day on average (1 standard drink = 10 grams or 1 unit of alcohol History or symptoms of any significant disease or disorder History of active malignancy within the last 5 years, except for localized or in situ carcinoma (e.g. basal or squamous cell carcinoma of the skin) Positive for hepatitis B or HIV infection, and/ or for HCV for healthy volunteers (Part A) For HCV patients: Decompensated liver disease or impaired liver function as defined by any history of ascites, hepatic encephalopathy, hepatocellular carcinoma or bleeding esophageal varices, or prothrombin international normalized ratio (PTINR) &gt;/= 2.0 at screening Evidence of cirrhosis and/or incomplete transition to cirrhosis Presence or history of nonhepatitis C liver disease</criteria>
	<gender>All</gender>
	<minimum_age>18 Years</minimum_age>
	<maximum_age>60 Years</maximum_age>
	<verification_date>November 2016</verification_date>
</DOC>